Abstract
Lung cancer, the third most common cancer, is the leading cause of cancer-related mortality and is frequently a disease of older patients [1]. As a result of the under-representation of older patients with lung cancer in clinical trials, there is a lack of scientific knowledge on how to select this patient group for different anticancer strategies [2]. It is critical to recommend appropriate treatment after evaluating frailty, life expectancy, and treatment-related potential toxicities for older patients with lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
